Sichuan Credit Pharmaceutical

Sichuan Credit Pharmaceutical specializes in the development, manufacturing, and marketing of pharmaceuticals focused on central nervous system disorders and immune-related diseases. Its portfolio includes small molecule drugs such as tizanidine hydrochloride and tandospirone citrate—both targeting CNS conditions—with one at NDA/BLA stage and another at IND application. The company also produces anti-tumor solid preparations and traditional Chinese medicines. Through its joint venture with ChemWerth Inc., it has expanded into international markets with APIs including oncology agents. The company operates under GMP standards and has passed both SFDA and FDA inspections.